Sandoz is a global pharmaceutical company specializing in generic and biosimilar medicines. The ultimate parent company is Sandoz Group AG, a public company headquartered in Basel, Switzerland, which traces its origins to 1886. It became an independent, publicly-traded company (SIX: SDZ) in October 2023 following a 100% spin-off from its former parent, Novartis. For fiscal year 2023, Sandoz Group AG reported revenue of approximately $9.6 billion and had over 23,000 employees globally. The specific entity named in litigation, Sandoz Private Ltd, is an India-based subsidiary incorporated in 1995, which plays a strategic role in the parent company's global manufacturing, research, and development.
As a leader in off-patent medicines, Sandoz develops, manufactures, and markets a broad portfolio of pharmaceuticals after patents on the original branded drugs expire. Its two main business segments are Generics and Biosimilars. The Generics division produces a wide range of products including antibiotics, cardiovascular treatments, and central nervous system disorder medicines in various forms like tablets, injectables, and inhalers. The Biosimilars division develops "similar" versions of complex biologic medicines used to treat diseases like cancer and arthritis. Sandoz pioneered the biosimilar market, launching the first biosimilar in Europe (2006) and the United States (2015).
Sandoz’s patent litigation posture is that of an operating company on the defense. The provided data shows the company as a defendant in its only tracked case and as a plaintiff in none. This is consistent with its business model, which often involves challenging existing patents on branded drugs to bring lower-cost generic alternatives to market. Such challenges frequently result in patent infringement lawsuits filed by the original drug manufacturer against Sandoz.
The company's single tracked case, Harmony Biosciences Management Inc et al. v. AET Pharma US Inc et al., filed in April 2026 in the District of Delaware, fits this pattern. As a defendant in this suit, Sandoz is likely involved in litigation related to its efforts to gain regulatory approval for a generic version of a drug marketed by Harmony Biosciences. This type of litigation is a standard part of the competitive landscape for generic and biosimilar manufacturers.